The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).
“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.
Limited physical function, fatigue, mental health issues (resulting from chronic disease), and medication issues can further affect the ability of children with rheumatic disease from performing well in school.
Karen Onel, MD, one of the lead investigators of the ACR's recent JIA treatment guidelines updates, explains important changes, treating patients with glucocorticoids, and the continued unmet needs in pediatric rheumatology.
The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.
As telehealth is an emerging and rapidly changing form of pediatric rheumatology care, engaging patients, caregivers, and rheumatologists will help streamline care to improve satisfaction and overall experience.